Myeloproliferative Neoplasm, Unclassifiable
Associated Genetic Biomarkers
NCI Definition: This subgroup of myeloproliferative neoplasms includes cases which do not meet the morphologic criteria of any of the defined myeloproliferative neoplasms, or which have characteristics that overlap at least two of the myeloproliferative neoplasms. 
Myeloproliferative neoplasm, unclassifiables most frequently harbor alterations in JAK2, ASXL1, TET2, U2AF1, and SRSF2 .
JAK2 V617F, JAK2 Mutation, JAK2 Exon 14 Mutation, ASXL1fs, and TET2 Mutation are the most common alterations in myeloproliferative neoplasm, unclassifiable .
There is 1 clinical trial for myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are completed or closed. Of the trial that contains myeloproliferative neoplasm, unclassifiable as an inclusion criterion, 1 is phase 1 (1 open).
BCR-ABL1, PML-RARA, and t(15;17)(q22;q12) are the most frequent gene inclusion criteria for myeloproliferative neoplasm, unclassifiable clinical trials .
Tas1553 is the most common intervention in myeloproliferative neoplasm, unclassifiable clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.